Validation of the Composite Complete Response (ccr) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database